Current Performance: AnaptysBio (NASDAQ: ANAB)

The long-term trend of the EPS is a vital number as it helps understand the future potential of AnaptysBio. The EPS growth rate, as it is typically called, is usually expressed as a percentage, which at this time is hard to estimate, but revenue growth has been -32.20% over the last twelve months. The long-term trend in EPS shows how well the management of AnaptysBio is adding value for shareholders.

AnaptysBio is in the biotechnology industry and trades as part of the healthcare sector. The company CEO is Hamza Suria. AnaptysBio Inc is a biotechnology company. The company is engaged in developing first-in-ntibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. Its product include ANB020 and ANB019.

Previous Intraday Performance:

The ANAB shares had a previous change of -1.75% which opened at 69.53 and closed at 68.89. It moved to an intraday high of 70.47 and a low of 68.01.

SeekingAlpha:  XBiotech: Strong Upside Potential In Atopic Dermatitis And Hidradenitis Suppurativa

Historical Performance:

Over the last five trading days, ANAB shares returned -0.82% and in the past 30 trading days it returned 11.54%. Over three months, it changed -1.03%. In one year it has changed -37.66% and within that year its 52-week high was 134.00 and its 52-week low was 54.26. ANAB stock is 26.96% above its 52 Week Low.

Our calculations result in a 200 day moving average of 78.35 and a 50 day moving average of 68.24. Right now, ANAB stock is trading -12.07% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  XBiotech: Strong Upside Potential In Atopic Dermatitis And Hidradenitis Suppurativa


The company has a market cap of $1.8b with 26.8m shares outstanding and a float of 26.2m shares. Trading volume was 181,252 shares and has experienced an average volume of 273,135 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.


The last annual reported EPS for AnaptysBio was -1.61 which ended on 31st of December 2017. Based on 6 analyst estimates, the consensus EPS for the next quarter is -0.91.

Below was the last reported quarterly earnings per share:
09-30-2018:  -0.66
06-30-2018:  -0.57
03-31-2018:  -0.63
12-31-2017:  -0.30

Indicators Also to Watch:

Based on the latest filings, there is 173.40% of institutional ownership.

I calculated the beta to be 2.38

SeekingAlpha:  Alexanders reports Q3 results

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -17.17%, return on assets is -16.01%, price-to-sales is 375.16 and price-to-book is 3.69.

Company Score Card:

Results are out of six:
 2  : Growth Expectations Result
 5  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Tags: , , ,

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *